Schrodinger AI Stock Analysis
Want to see SDGR full AI Analyst Report?
Schrodinger (SDGR) AI Stock Analysis
Schrodinger
(NASDAQ:SDGR)
The score is primarily held back by weak profitability and a return to negative operating/free cash flow, despite improving revenue momentum and a reasonable balance-sheet cushion. Technicals are supportive with the stock trading above major moving averages and positive momentum indicators. The latest earnings call adds a positive tilt due to raised guidance and expense discipline, but valuation remains constrained by current unprofitability and the lack of dividend support.
Schrodinger Key Performance Indicators (KPIs)
Revenue by GeographyBreaks down sales by region to identify where customers and growth are concentrated and to assess exposure to local regulatory, currency, and market cycles. Shifts across regions can signal new market penetration or rising risk from dependence on a particular geography or customer base.
EMEA is the clear driver of the large, lumpy swings — recent spikes reflect collaboration/drug‑discovery milestone recognition rather than steady regional software traction. Underneath, ACV growth and a deliberate shift to hosted licensing signal strengthening recurring demand that should smooth future geography volatility, but the hosted transition will depress near‑term recognized revenue and gross margins. Treat quarterly geographic spikes as milestone timing noise; focus on ACV, hosted mix, and announced collaboration exits for forward value.
The FlySchrodinger (SDGR) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $2.08B
- Dividend Yield
- ―
- Average Volume (3M)
- 2.04M
- Price to Earnings (P/E)
- -39.9
- Beta (1Y)
- 1.81
- Revenue Growth
- 4.77%
- EPS Growth
- 66.98%
- Country
- US
- Employees
- 850
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Software - Application
Schrodinger Business Overview & Revenue Model
Company Description
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Af...
How the Company Makes Money
Schrödinger makes money through a combination of (1) software revenue and (2) drug discovery revenue. Software revenue is primarily generated by licensing access to its computational platform and applications to customers (typically under term licens...
Schrodinger Earnings Call Summary
The call was strongly positive overall. The company reported broad-based ACV and revenue growth, raised full-year ACV and drug discovery revenue guidance, reduced operating expenses, expanded hosted licensing, and cited strong progress in Bunsen, predictive toxicology, material science, and its therapeutics portfolio. The main negatives were the higher net loss, lower software gross margin during the hosted transition, mark-to-market other expense, limited visibility into Bunsen monetization and future milestone timing, and the earlier stage of material science adoption.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For full year 2026, the company now expects ACV to be in the range of $222 million to $232 million, representing 12% to 17% growth over 2025; drug discovery revenue is expected to be in the range of $75 million to $85 million, compared to the prior expectation of $65 million to $75 million; and operating expenses are still expected to be less than 2025. The company outlined a 3-year view of $150 million of revenue over the next 3 years for drug discovery, with a baseline of roughly $50 million a year, while noting that milestones are harder to have visibility into, and expects to have the open beta for Bunsen this year.
Schrodinger Financial Statement Overview
Summary
Revenue momentum has improved and gross margins remain healthy, supported by a balance sheet with manageable leverage. However, profitability remains weak (negative net margin and negative EBIT/EBITDA) and cash generation has deteriorated again in the latest TTM period with operating cash flow and free cash flow turning negative, increasing execution risk.
Income Statement
44NeutralBalance Sheet
68PositiveCash Flow
38Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 269.20M | 255.87M | 207.54M | 216.67M | 180.96M | 137.93M |
| Gross Profit | 157.53M | 142.61M | 132.08M | 140.69M | 101.02M | 65.62M |
| EBITDA | -50.99M | -96.30M | -179.55M | 48.47M | -144.78M | -97.96M |
| Net Income | -59.25M | -103.27M | -187.12M | 40.72M | -149.19M | -100.39M |
Balance Sheet | ||||||
| Total Assets | 611.94M | 726.16M | 823.23M | 802.96M | 688.59M | 756.49M |
| Cash, Cash Equivalents and Short-Term Investments | 366.36M | 395.46M | 352.12M | 463.00M | 451.09M | 576.48M |
| Total Debt | 104.63M | 109.23M | 117.83M | 127.88M | 116.49M | 79.87M |
| Total Liabilities | 310.11M | 362.11M | 401.78M | 254.40M | 240.68M | 199.40M |
| Stockholders Equity | 301.83M | 364.05M | 421.44M | 548.56M | 447.89M | 557.07M |
Cash Flow | ||||||
| Free Cash Flow | -18.97M | 12.46M | -164.68M | -150.14M | -127.70M | -77.84M |
| Operating Cash Flow | -14.77M | 13.90M | -157.37M | -136.73M | -119.68M | -70.67M |
| Investing Cash Flow | 180.57M | 57.90M | 148.84M | 193.03M | 90.02M | -16.81M |
| Financing Cash Flow | 4.14M | 2.93M | 10.12M | 9.05M | 2.11M | 7.95M |
Schrodinger Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SDGR, the sentiment is Positive. The current price of 31.52 is above the 20-day moving average (MA) of 27.10, above the 50-day MA of 26.55, and above the 200-day MA of 17.29, indicating a bullish trend. The MACD of 1.53 indicates Negative momentum. The RSI at 60.42 is Neutral, neither overbought nor oversold. The STOCH value of 82.53 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SDGR.
Schrodinger Risk Analysis
Schrodinger disclosed 87 risk factors in its most recent earnings report. Schrodinger reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksSchrodinger Peers Comparison
Overall Rating
RSSS68Neutral- SDGR60Neutral
AI51.7Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| RSSS | 68Neutral | $61.11M | 21.75 | 15.55% | ― | -1.53% | 140.44% |
| SDGR | 60Neutral | $2.43B | -39.90 | -18.11% | ― | 4.77% | 66.98% |
| AI | 52Neutral | $1.90B | -3.94 | -62.87% | ― | -37.55% | -18.96% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SDGR | Schrodinger, Inc. | 31.52 | 14.32 | 83.26% | |
| RSSS | Research Solutions | 1.94 | -1.17 | -37.62% | |
| AI | C3.Ai, Inc. | 12.19 | -1.91 | -13.55% |
Schrodinger Corporate Events
Schrödinger Clarifies Clinical Study Status and Reports Third-Quarter Results
NeutralOn November 4, 2026, Schrödinger corrected an American Society of Hematology abstract, clarifying that it had not initiated a combination study of SGR-1505 in relapsed/refractory B-cell malignancies under its FDA-cleared protocol. Also on November 4,...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026